← daily scanner dashboard

#9 EXEL — EXELIXIS, INC.

A2_VCP_NEAR_PIVOT | as of 2026-10-02 | automated relative priority, not a published Minervini point formula

Relative priority45.83
RS rating77.44
Fundamental strength16.67
VCP score84.13
Pivot distance1.28%
AV confirmation80.00%complete
Technical chart for EXEL

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close58.39
sma5055.83
sma15050.79
sma20049.08
sma200_1m_ago47.40
pct_above_52w_low72.96
pct_below_52w_high4.50
rs_rating77.44

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupFAIL
atr_contractingFAIL
price_tightPASS
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[8.66, 4.89]
depth_ratios_vs_prior[0.565]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high59.72
base_low54.55
base_depth_pct8.66
base_duration_weeks4.10
resistance_spread_pct0.95
volume_dryup_ratio_10d_vs_50d0.81
atr_pct_recent2.88
atr_pct_prior3.04
atr_contraction_ratio0.95
tight_10d_range_pct8.67
raw_contraction_count11.00
raw_depths_pct[5.57, 8.36, 6.62, 9.18, 5.8, 5.52, 4.49, 12.26, 6.1, 8.66, 4.89]
final_trough_age_bars7.00
selection_reasoncoherent_current_sequence
pivot_price59.15
distance_to_pivot_pct1.28
vcp_score_pct84.13
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-0.24
return_3m_pct5.15
return_6m_pct33.07
return_12m_pct41.72
weighted_12m_momentum8.67
range_10d_pct8.67
range_20d_pct12.08
avg_volume_50d2.37M
dollar_volume_50d138.12M
up_down_volume_ratio_50d1.36
accumulation_days_20d2.00
distribution_days_20d3.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingFAIL
sales_acceleratingPASS
gross_margin_improvingPASS
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct26.15
eps_previous_q_yoy_growth_pct43.64
eps_acceleration_pts-17.48
eps_annual_growth_pct57.95
eps_cagr_3y_pct70.59
sales_growth_yoy_pct10.63
sales_previous_q_yoy_growth_pct9.97
sales_acceleration_pts0.67
sales_annual_growth_pct6.98
sales_cagr_3y_pct12.93
gross_margin_pct96.71
operating_margin_pct39.51
pretax_margin_pct—
net_margin_pct33.73
gross_margin_yoy_change_pts0.14
operating_margin_yoy_change_pts1.93
roe_latest_fy_pct35.53
current_ratio3.46
debt_to_equity_pct—
cash_to_debt—
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": null, "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": "us-gaap:CostOfGoodsAndServicesSold", "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": "us-gaap:GrossProfit", "inventory": "us-gaap:InventoryNet", "long_term_debt": "us-gaap:LongTermDebtNoncurrent", "long_term_debt_current": "us-gaap:LongTermDebtCurrent", "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "sga": "us-gaap:SellingGeneralAndAdministrativeExpense", "share_repurchases": "us-gaap:PaymentsForRepurchaseOfCommonStock", "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": null, "short_term_investments": "us-gaap:ShortTermInvestments", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["accounts_receivable", "dividends_paid", "short_term_debt"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-07-03
latest_quarter_filed2026-08-05
latest_fiscal_year_end2026-01-02
latest_balance_sheet_end2026-07-03

Company metadata

symbolEXEL
cik939,767
company_nameEXELIXIS, INC.
exchange—
sic2,836
sic_descriptionBiological Products, (No Diagnostic Substances)
fiscal_year_end101.00
as_of2026-10-04
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-08-05
latest_reported_eps0.82
latest_estimated_eps0.75
latest_earnings_surprise_pct9.33
avg_earnings_surprise_4q_pct14.07
positive_earnings_surprises_4q4.00
earnings_surprise_quarters_available4.00
reported_eps_yoy_growth_pct9.33
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days4.00
estimate_revision.eps_estimate_revision_up_trailing_30_days5.00
estimate_revision.eps_estimate_revision_down_trailing_30_days6.00
eps_revision_up_30d5.00
eps_revision_down_30d6.00
eps_revision_net_up_30d-1.00
institutional.total_institutional_holders849.00
institutional.total_institutional_shares287.51M
institutional.holders_with_increased_holdings400.00
institutional.holders_with_decreased_holdings359.00
institutional.holders_with_unchanged_holdings90.00
institutional_holder_rows849.00
institutional_total_shares287.51M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dFAIL
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct80.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-09-0359.722026-09-1154.558.66—5.00
2026-09-1859.152026-09-2356.264.890.563.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
8-K2026-09-110000939767-26-000108exel-20260910.htm
8-K2026-08-310000939767-26-000104exel-20260831.htm
10-Q2026-08-050000939767-26-000098exel-20260703.htm
8-K2026-08-050000939767-26-000096exel-20260805.htm
8-K2026-05-290000939767-26-000074exel-20260526.htm
10-Q2026-05-050000939767-26-000059exel-20260403.htm
8-K2026-05-050000939767-26-000058exel-20260505.htm
10-K2026-02-100000939767-26-000021exel-20260102.htm
8-K2026-02-100000939767-26-000019exel-20260210.htm
8-K2026-01-120000939767-26-000003exel-20260111.htm
8-K2025-11-070000939767-25-000133exel-20251104.htm
10-Q2025-11-040000939767-25-000128exel-20251003.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: